March 23, 2018 / 12:53 PM / a month ago

BRIEF-EMA Panel Recommends Conditional Approval Of Clovis Oncology Ovarian Cancer Drug Rubraca

Reuters Staff

1 Min Read

March 23 (Reuters) - EU Medicines Agency:

* RECOMMENDS APPROVAL OF CLOVIS ONCOLOGY OVARIAN CANCER DRUG RUBRACA

* EU MEDICINES AGENCY SAYS RECOMMENDED GRANTING A CONDITIONAL MARKETING AUTHORISATION FOR CLOVIS OVARIAN CANCER DRUG RUBRACA Source text - (bit.ly/2pBz519) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.